Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with significant unmet medical needs [4] Group 1: Company Overview - Chemomab is developing nebokitug, a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [4] - Nebokitug has shown a favorable safety profile and has been well-tolerated in clinical and preclinical studies, with potential applications in multiple severe fibro-inflammatory diseases [4] - The company has reported positive results from five clinical trials of nebokitug, particularly from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [4] - Chemomab is preparing to initiate a Phase 3 trial for nebokitug in PSC, which is designed as a single pivotal trial with a clear pathway to regulatory approval [4] - Nebokitug has received Orphan Drug and Fast Track designations from the FDA and EMA for the treatment of PSC [4] Group 2: Upcoming Events - Co-founder and CEO Adi Mor will participate in Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City [1][3] - Dr. Mor will present a corporate overview and will be available for one-on-one meetings with registered attendees during the summit [2][3]

Core Insights - Chemomab Therapeutics announced new clinical data from the Phase 2 SPRING trial of nebokitug for primary sclerosing cholangitis (PSC), showing favorable safety and consistent improvements in key biomarkers over 48 weeks of treatment [1][2] Group 1: Clinical Trial Results - The open-label extension (OLE) of the SPRING trial demonstrated that nebokitug was well-tolerated and maintained its anti-inflammatory and anti-fibrotic effects for up to 48 weeks, with significant improvements in biomarkers such as ELF score and liver stiffness [2][3] - Out of 54 eligible patients who completed the initial 15-week double-blind portion, 50 chose to continue in the OLE, receiving up to 33 additional weeks of treatment [3] - The results support the evaluation of nebokitug at a dosage of 20 mg/kg in a Phase 3 trial for PSC patients [3] Group 2: Mechanism of Action - Nebokitug targets macrophage-mediated mechanisms in PSC, showing dose-dependent reductions in serum macrophage-related proteins, particularly in patients with moderate to advanced disease [4][5] - The treatment led to increased expression of macrophage stimulating protein 1 (MST1), which is functionally impaired in PSC patients due to a genetic variant [6] - Changes in MST1 levels were associated with improvements in liver stiffness measurements, indicating its potential as a biomarker for nebokitug's activity [6] Group 3: Future Directions - Chemomab is preparing for a Phase 3 trial based on positive data from the Phase 2 SPRING trial, with a focus on a clinical event primary endpoint to streamline regulatory approval [10] - Nebokitug has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC treatment, highlighting its potential in addressing unmet medical needs [10]

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference, with a prerecorded presentation available starting September 5, 2025 [1][2] Company Overview - Chemomab is developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, indicating its potential to treat severe fibro-inflammatory diseases [3] - The company has reported positive results from five clinical trials of nebokitug, particularly from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [3] - Chemomab is preparing for a potential Phase 3 trial in PSC, which will be a single pivotal trial with a clinical event primary endpoint, aiming for full regulatory approval [3] - Nebokitug has received Orphan Drug designation from the FDA and EMA, as well as Fast Track designation from the FDA for the treatment of PSC [3] - The program for treating systemic sclerosis with nebokitug has an open U.S. IND [3]

Core Insights - The SPRING trial data presented at Digestive Disease Week 2025 indicates that nebokitug is well-tolerated and shows significant improvements in multiple biomarkers related to fibrotic and inflammatory diseases, suggesting its potential as a first-in-class treatment for primary sclerosing cholangitis (PSC) [1][2][4] Group 1: Clinical Trial Results - The Phase 2 SPRING trial data demonstrated that nebokitug was safe and well-tolerated over a 48-week treatment period, with a safety profile comparable to placebo [2][3] - Nebokitug exhibited dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects, particularly in patients with moderate to severe disease, showing sustained improvements in biomarkers associated with disease progression [2][3] - In the open-label extension of the study, patients receiving nebokitug for up to 48 weeks showed continual improvement in fibrosis markers and stabilization of liver stiffness, especially at the 20 mg/kg dose [3] Group 2: Company Overview and Future Plans - Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug being a dual activity monoclonal antibody targeting CCL24 [8] - The company is preparing for a potential Phase 3 trial for nebokitug based on positive results from the Phase 2 SPRING trial, which has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment [8] - The Phase 3 trial design aims for a single pivotal trial with a clinical event primary endpoint, providing a streamlined pathway to potential full regulatory approval [8]